PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma

Human Pathology

Volumn 40, Issue 10, 2009, Pages 1434-1440

  Galgano, Mary T ^a   Conaway, Mark ^a   Spencer, Adam M ^b   Paschal, Bryce M ^b   Frierson Jr , Henry F ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Androgen receptor; Immunohistochemistry; Ovarian cancer; PI 3 kinase; PRK1; Prostate cancer

Indexed keywords

PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE N; PROTEIN PRK1; PROTEIN PRK2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; OVARIAN SEROUS CARCINOMA; OVARY CARCINOMA; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY;

BLOTTING, WESTERN; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS; OVARIAN NEOPLASMS; PROTEIN KINASE C; RNA, MESSENGER; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 69949119623     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.02.008     Document Type: Article

References (24)

1. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4 (2005) 988-1004
2. Samuels Y., and Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18 (2006) 77-82
3. Lee S., Choi E.J., Jin C., and Kim D.H. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 97 (2005) 26-34
4. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
5. Nakayama K., Nakayama N., Kurman R.J., et al. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 5 (2006) 779-785
6. Bellacosa A., de Feo D., Godwin A.K., et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64 (1995) 280-285
7. Mellor H., and Parker P.J. The extended protein kinase C superfamily. Biochem J 332 Pt 2 (1998) 281-292
8. Metzger E., Yin N., Wissmann M., et al. Phosphorylation of histone H3 at threonine 11 establishes a novel chromatin mark for transcriptional regulation. Nat Cell Biol 10 (2008) 53-60
9. Metzger E., Muller J.M., Ferrari S., Buettner R., and Schule R. A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer. EMBO J 22 (2003) 270-280
10. Leenders F., Mopert K., Schmiedeknecht A., et al. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J 23 (2004) 3303-3313
11. Helzlouer K.J., Alberq A.J., Gordon G.B., et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 274 (1995) 1926-1930
12. Schildkraut J.M., Schwingl P.J., Bastos E., Evanoff A., and Hughes C. Epithelial ovarian cancer risk among women with polycystic ovarian syndrome. Obstet Gynecol 88 (1996) 554-559
13. Levine D.A., and Boyd J. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Cancer Res 61 (2001) 908-911
14. Li A.J., Scoles D.R., Armstrong K.U., and Karlan B.Y. Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas. Gynecol Oncol 109 (2008) 220-225
15. Su A., Welsh J., Sapinoso L., et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 61 (2001) 7388-7393
16. Welsh J., Zarrinkar P., Sapinoso L., et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 98 (2001) 1176-1181
17. Lockhart D., Dong H., Byrne H., et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14 (1996) 1675-1680
18. Wodicka L., Dong H., Mittmann M., Ho M., and Lockhart D. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 15 (1997) 1359-1367
19. Wang Y., Yang J., Gao Y., et al. Reciprocal regulation of 5alpha-dihydrotestosterone, interleukin-6 and interleukin-8 during proliferation of epithelial ovarian carcinoma. Cancer Biol Ther 6 (2007) 864-871
20. Edmondson R.J., Monaghan J.M., and Davies B.R. The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer 86 (2002) 879-885
21. Ahonen M.H., Zhuang Y.H., Aine R., Ylikomi T., and Tuohimaa P. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer 86 (2000) 40-46
22. Jazaeri A.A., Yee C.J., Sotiriou C., et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 94 (2002) 990-1000
23. Lu K.H., Patterson A.P., Wang L., et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10 (2004) 3291-3300
24. Zhang L., Huang J., Yang N., et al. Integrative genomic analysis of phosphatidylinositol 3′-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 13 (2007) 5314-5321